TY - JOUR T1 - 5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study. JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 926 LP - 928 DO - 10.1136/ard.49.11.926 VL - 49 IS - 11 AU - J A Casas AU - P A Saway AU - I Villarreal AU - C Nolte AU - B L Menajovsky AU - E E Escudero AU - W D Blackburn AU - G S Alarcón AU - C P Subauste Y1 - 1990/11/01 UR - http://ard.bmj.com/content/49/11/926.abstract N2 - A six month controlled study of 5-fluorouracil in the treatment of scleroderma showed a modest benefit in skin scores, Raynaud's phenomenon, and patients' global assessment. Visceral organ and hand function were unaffected. Mild to moderate toxicity was common in the 5-fluorouracil treated patients but usually responded to dose reduction. Two patients receiving 5-fluorouracil died from causes seemingly unrelated to treatment. Significant clinical improvement in scleroderma was not noted in the first six months of treatment with 5-fluorouracil. ER -